KEYNOTE-224

NCT02702414 📎

Regimen

Experimental
pembrolizumab 200 mg IV Q3W

Population

Advanced hepatocellular carcinoma previously treated with sorafenib (intolerant or progressed), ECOG 0-1, Child-Pugh A. Single-arm phase 2.

Key finding

ORR 17% (95% CI 11-26); 1% CR, 16% PR, 44% SD; grade 3+ TRAE ~24%; supported **FDA accelerated approval Nov 2018** for 2L post-sorafenib HCC; etiology mixed (HBV 22%, HCV 26%, non-viral ~45%)

Source: PMID 29875066

Timeline

    Guideline citations

    • NCCN HCC (p.18)